[1] |
ALAMMAR N, STEIN E. Irritable bowel syndrome:what treatments really work[J]. Med Clin North Am, 2019, 103(1):137-152. DOI: 10.1016/j.mcna.2018.08.006.
|
[2] |
SIMRÉN M, TÖRNBLOM H, PALSSON O S,et al. Management of the multiple symptoms of irritable bowel syndrome[J]. Lancet Gastroenterol Hepatol, 2017, 2(2):112-122. DOI: 10.1016/S2468-1253(16)30116-9.
|
[3] |
|
[4] |
SULTAN S, MALHOTRA A. Irritable bowel syndrome[J]. Ann Intern Med, 2017, 166(11):ITC81-96. DOI: 10.7326/AITC201706060.
|
[5] |
HÄUSER W, MARSCHALL U, LAYER P,et al. The prevalence,comorbidity,management and costs of irritable bowel syndrome[J]. Dtsch Arztebl Int, 2019, 116(27/28):463-470. DOI: 10.3238/arztebl.2019.0463.
|
[6] |
GWEE K A, GHOSHAL U C, CHEN M H. Irritable bowel syndrome in Asia:pathogenesis,natural history,epidemiology,and management[J]. J Gastroenterol Hepatol, 2018, 33(1):99-110. DOI: 10.1111/jgh.13987.
|
[7] |
FLACCO M E, MANZOLI L, DE GIORGIO R,et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage:a meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2019, 23(7):2986-3000. DOI: 10.26355/eurrev_201904_17580.
|
[8] |
ZHANG F, XIANG W, LI C Y,et al. Economic burden of irritable bowel syndrome in China[J]. World J Gastroenterol, 2016, 22(47):10450-10460. DOI: 10.3748/wjg.v22.i47.10450.
|
[9] |
PEERY A F, CROCKETT S D, MURPHY C C,et al. Burden and cost of gastrointestinal,liver,and pancreatic diseases in the United States:update 2018[J]. Gastroenterology, 2019, 156(1):254-272.e11. DOI: 10.1053/j.gastro.2018.08.063.
|
[10] |
BLACK C J, STAUDACHER H M, FORD A C. Efficacy of a low FODMAP diet in irritable bowel syndrome:systematic review and network meta-analysis[J]. Gut, 2021. DOI: 10.1136/gutjnl-2021-325214.
|
[11] |
CHEN M, TANG T C, QIN D,et al. Pharmacologic treatments for irritable bowel syndrome:an umbrella systematic review[J]. J Gastrointestin Liver Dis, 2020, 29(2):199-209. DOI: 10.15403/jgld-817.
|
[12] |
WU I X Y, WONG C H L, HO R S T,et al. Acupuncture and related therapies for treating irritable bowel syndrome:overview of systematic reviews and network meta-analysis[J]. Therap Adv Gastroenterol, 2019, 12:1756284818820438. DOI: 10.1177/1756284818820438.
|
[13] |
NEUMAN H B, GREENBERG C C. Comparative effectiveness research:opportunities in surgical oncology[J]. Semin Radiat Oncol, 2014, 24(1):43-48. DOI: 10.1016/j.semradonc.2013.09.003.
|
[14] |
NACI H, SALCHER-KONRAD M, KESSELHEIM A S,et al. Generating comparative evidence on new drugs and devices before approval[J]. Lancet, 2020, 395(10228):986-997. DOI: 10.1016/S0140-6736(19)33178-2.
|
[15] |
CIPRIANI A, IOANNIDIS J P A, ROTHWELL P M,et al. Generating comparative evidence on new drugs and devices after approval[J]. Lancet, 2020, 395(10228):998-1010. DOI: 10.1016/S0140-6736(19)33177-0.
|
[16] |
MANHEIMER E, WIELAND L S, CHENG K,et al. Acupuncture for irritable bowel syndrome:systematic review and meta-analysis[J]. Am J Gastroenterol, 2012, 107(6):835-848. DOI: 10.1038/ajg.2012.66.
|
[17] |
YAN J, MIAO Z W, LU J,et al. Acupuncture plus Chinese herbal medicine for irritable bowel syndrome with diarrhea:a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med, 2019, 2019:7680963. DOI: 10.1155/2019/7680963.
|
[18] |
GABER C E, KINLAW A C, EDWARDS J K,et al. Comparative effectiveness and harms of antibiotics for outpatient diverticulitis:two nationwide cohort studies[J]. Ann Intern Med, 2021, 174(6):737-746. DOI: 10.7326/M20-6315.
|
[19] |
DESAI R J, FRANKLIN J M. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score:a primer for practitioners[J]. BMJ, 2019, 367:l5657. DOI: 10.1136/bmj.l5657.
|
[20] |
WANG Y Y, LIU Y T, LV Q Q,et al. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan,China:a retrospective,single-center study with propensity score matching[J]. Phytomedicine, 2021, 85:153404. DOI: 10.1016/j.phymed.2020.153404.
|
[21] |
XU L L, ZHANG S F, WANG Y L,et al. The efficacy of long-term Chinese herbal medicine use on lung cancer survival time:a retrospective two-center cohort study with propensity score matching[J]. Evid Based Complement Alternat Med, 2021, 2021:5522934. DOI: 10.1155/2021/5522934.
|
[22] |
GUO J C, PAN H C, YEH B Y,et al. Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients:a retrospective population-based cohort study[J]. Front Pharmacol, 2021, 12:616522. DOI: 10.3389/fphar.2021.616522.
|
[23] |
WU Y B, DAI Y K, ZHANG L,et al. Pharmacological treatments of Chinese herbal medicine for irritable bowel syndrome in adults:a network meta-analysis of randomized controlled trials[J]. PLoS One, 2021, 16(8):e0255665. DOI: 10.1371/journal.pone.0255665.
|
[24] |
PEI L X, GENG H, GUO J,et al. Effect of acupuncture in patients with irritable bowel syndrome:a randomized controlled trial[J]. Mayo Clin Proc, 2020, 95(8):1671-1683. DOI: 10.1016/j.mayocp.2020.01.042.
|
[25] |
LIU B Y, WU J N, YAN S Y,et al. Electroacupuncture vs prucalopride for severe chronic constipation:a multicenter,randomized,controlled,noninferiority trial[J]. Am J Gastroenterol, 2021, 116(5):1024-1035. DOI: 10.14309/ajg.0000000000001050.
|
[26] |
CHEN Y D, JIN X Q, YU M H,et al. Acupuncture for moderate to severe allergic rhinitis:a non-randomized controlled trial[J]. Chin J Integr Med, 2016, 22(7):518-524. DOI: 10.1007/s11655-016-2453-x.
|
[27] |
SIGNOROVITCH J E, WU E Q, BETTS K A,et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia:a matching-adjusted indirect comparison of randomized trials[J]. Curr Med Res Opin, 2011, 27(6):1263-1271. DOI: 10.1185/03007995.2011.576238.
|
[28] |
FIORE L D, LAVORI P W. Integrating randomized comparative effectiveness research with patient care[J]. N Engl J Med, 2016, 374(22):2152-2158. DOI: 10.1056/NEJMra1510057.
|
[29] |
陈敏. 针刺治疗肠易激综合征病例注册登记研究[EB/OL]. [2022-01-03].
|
[30] |
|
[31] |
KNOTTNERUS J A, TUGWELL P. Comparative effectiveness research requires competitive effectiveness[J]. J Clin Epidemiol, 2018, 94:v-vi. DOI: 10.1016/j.jclinepi.2018.01.005.
|
[32] |
ALMARIO C V, SPIEGEL B M R. Employing irritable bowel syndrome patient-reported outcomes in the clinical trenches[J]. Clin Gastroenterol Hepatol, 2018, 16(4):462-466.e2. DOI: 10.1016/j.cgh.2017.12.026.
|
[33] |
|
[34] |
|
[35] |
|